Is fezolinetant available in Chinese pharmacies?

Fezolinetant has not yet been launched in the Chinese market. Therefore, domestic patients cannot purchase the drug directly from domestic pharmacies through formal channels. Fezonatant has been approved in multiple international markets, especially in the European and American markets. The drug has been widely used to treat vasomotor symptoms caused by menopause, especially the relief of hot flashes. However, the China Food and Drug Administration (NMPA) has not approved the drug for marketing, so domestic patients can only choose to obtain the drug through international drug purchase channels.

In overseas markets, the original version of Fezonatant is produced by Ipsen Pharmaceutical Company. The current common specification is 45mg*30 tablets, and the price is about more than 600 US dollars, which is equivalent to more than 3,000 yuan in RMB (the price may vary due to exchange rate fluctuations). This price is relatively high for patients who require treatment, and due to the cumbersome process of purchasing drugs internationally, patients may also need to bear additional customs duties and transportation costs.

In addition to original drugs, there are also some generic versions on the market, mainly produced by pharmaceutical companies in some Asian countries, such as Lucius Pharmaceuticals in Laos. The price of generic drugs is relatively low, with the same specifications selling for about more than 900 yuan per box (also affected by exchange rate fluctuations). Although the ingredients of these generic drugs are basically the same as those of the original drugs, patients still need to be cautious when using them, and it is best to choose appropriate drugs under the guidance of a doctor.

In general, fezonatant is not currently on the market in China, and patients cannot purchase the drug in domestic pharmacies. If they need to use it, patients can only purchase it through overseas channels and face higher drug costs and related drug purchase risks. With the changes in international drug supervision and market dynamics, Fezonatant may enter the Chinese market in the future, but the specific launch time still needs to wait for relevant approvals.

Reference materials:https://www.drugs.com/mtm/fezolinetant.html